Interest in Continued Use After Participation in a Study of Over-the-Counter Progestin-Only Pills in the United States.

Autor:	Grindlay K; Ibis Reproductive Health, Cambridge, Massachusetts, USA., Key K; Ibis Reproductive Health, Cambridge, Massachusetts, USA., Zuniga C; Ibis Reproductive Health, Cambridge, Massachusetts, USA., Wollum A; Ibis Reproductive Health, Oakland, California, USA., Blanchard K; Ibis Reproductive Health, Cambridge, Massachusetts, USA., Grossman D; Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, Oakland, California, USA.
Jazyk:	angličtina
Zdroj:	Women's health reports (New Rochelle, N.Y.) [Womens Health Rep (New Rochelle)] 2022 Nov 09; Vol. 3 (1), pp. 904-914. Date of Electronic Publication: 2022 Nov 09 (Print Publication: 2022).
DOI:	10.1089/whr.2022.0056
Abstrakt:	Objective: To assess interest in continued use of over-the-counter progestin-only pills among individuals who used them in a trial. Methods: From January 2020 to September 2021, we conducted a cross-sectional online survey with individuals who completed participation in a trial evaluating over-the-counter use of norgestrel 0.075 mg tablets in the United States. We calculated descriptive statistics, Pearson's chi-square and Fisher's exact tests, and logistic regression models to assess likelihood of future over-the-counter progestin-only pill use, reasons for interest/noninterest, situations for over-the-counter progestin-only pill use, willingness to pay for an over-the-counter progestin-only pill, likelihood of future preventive health screenings, prior difficulties getting prescription contraception, and background characteristics. Results: Among 550 adult and 115 adolescent participants (75% response rate), 83% reported likelihood of future over-the-counter progestin-only pill use. Hispanic/Latinx and Black participants and adults with public insurance, prior pregnancies, and some college reported higher likelihood of future use compared with their counterparts. Among likely users, 90% were interested in long-term use and 79 % ≥ 25 years of age reported they would get future preventive screenings; participants would pay up to $20/month on average. Primary reasons for interest included convenience (81%), ease of access (80%), and saving time (77%) and money (64%). The primary reason for noninterest was bleeding associated with progestin-only pill use (52%). Conclusion: There was high interest in continuing to use over-the-counter progestin-only pills among individuals who had used them in a study. These findings highlight the real-world acceptability of taking a progestin-only pill without a prescription, and contribute to evidence supporting over-the-counter access. Competing Interests: Ibis Reproductive Health, where all study authors have an affiliation, has a partnership with HRA Pharma in which Ibis provided financial support for some of the research that will be part of the over-the-counter switch application to the U.S. FDA for a progestin-only pill. Ibis receives no monetary compensation nor ownership of any rights to the product. Ibis raised the funding for this partnership from a private foundation and selected HRA Pharma as its partner through an open process overseen by the Oral Contraceptives Over-the-Counter Working Group steering committee in an effort to incentivize a pharmaceutical company to complete the work to make a birth control pill available over the counter. (© Kate Grindlay et al., 2022; Published by Mary Ann Liebert, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu